Abstract
We performed whole-genome sequencing (WGS) in 327 children with cerebral palsy (CP) and their biological parents. We classified 37 of 327 (11.3%) children as having pathogenic/likely pathogenic (P/LP) variants and 58 of 327 (17.7%) as having variants of uncertain significance. Multiple classes of P/LP variants included single-nucleotide variants (SNVs)/indels (6.7%), copy number variations (3.4%) and mitochondrial mutations (1.5%). The COL4A1 gene had the most P/LP SNVs. We also analyzed two pediatric control cohorts (n = 203 trios and n = 89 sib-pair families) to provide a baseline for de novo mutation rates and genetic burden analyses, the latter of which demonstrated associations between de novo deleterious variants and genes related to the nervous system. An enrichment analysis revealed previously undescribed plausible candidate CP genes (SMOC1, KDM5B, BCL11A and CYP51A1). A multifactorial CP risk profile and substantial presence of P/LP variants combine to support WGS in the diagnostic work-up across all CP and related phenotypes.
Similar content being viewed by others
Data availability
WGS data from CP families from the Canadian CP Registry and control data from the CHILD cohort are available at the European Genome–Phenome Archive (EGA; Canadian CP Registry: https://ega-archive.org/dacs/EGAC00001003068; CHILD: https://ega-archive.org/dacs/EGAC00001002953). WGS data from CP-NET are stored in the Brain-CODE Neuroinformatics Platform (https://doi.org/10.60955/fszr-5q79)97. Access to the EGA datasets is governed by a Data Access Committee with primary contact via author S.W.S. Access to the Brain-CODE dataset is governed by a Data Access Committee managed by the Ontario Brain Institute, with primary contacts via authors R.F.W. and D.L.F. Control data from subjects enrolled in the Inova cohort were not consented for deposition in public databases and are thus available on request from author G.M. Source data are provided with this paper.
Code availability
The present study did not use any customized code or software.
References
McIntyre, S. et al. Global prevalence of cerebral palsy: a systematic analysis. Dev. Med. Child Neurol. 64, 1494–1506 (2022).
Rosenbaum, P. et al. A report: the definition and classification of cerebral palsy April 2006. Dev. Med. Child Neurol. Suppl. 109, 8–14 (2007).
Christensen, D. et al. Prevalence of cerebral palsy, co-occurring autism spectrum disorders, and motor functioning—Autism and Developmental Disabilities Monitoring Network, USA, 2008. Dev. Med. Child Neurol. 56, 59–65 (2014).
Jin, S. C. et al. Mutations disrupting neuritogenesis genes confer risk for cerebral palsy. Nat. Genet. 52, 1046–1056 (2020).
Amankwah, N. et al. Cerebral palsy in Canada, 2011–2031: results of a microsimulation modelling study of epidemiological and cost impacts. Health Promot. Chronic Dis. Prev. Can. 40, 25–37 (2020).
Friedman, J. M., van Essen, P. & van Karnebeek, C. D. M. Cerebral palsy and related neuromotor disorders: overview of genetic and genomic studies. Mol. Genet. Metab. https://doi.org/10.1016/j.ymgme.2021.11.001 (2021).
Chopra, M. et al. Mendelian etiologies identified with whole exome sequencing in cerebral palsy. Ann. Clin. Transl. Neurol. 9, 193–205 (2022).
Li, N. et al. In-depth analysis reveals complex molecular aetiology in a cohort of idiopathic cerebral palsy. Brain 145, 119–141 (2022).
Mei, H. et al. Genetic spectrum identified by exome sequencing in a Chinese pediatric cerebral palsy cohort. J. Pediatr. 242, 206–212.e206 (2022).
Rosello, M. et al. Hidden etiology of cerebral palsy: genetic and clinical heterogeneity and efficient diagnosis by next-generation sequencing. Pediatr. Res. 90, 284–288 (2021).
Segel, R. et al. Copy number variations in cryptogenic cerebral palsy. Neurology 84, 1660–1668 (2015).
May, H. J. et al. Genetic testing in individuals with cerebral palsy. Dev. Med. Child Neurol. 63, 1448–1455 (2021).
Moreno-De-Luca, A. et al. Molecular diagnostic yield of exome sequencing in patients with cerebral palsy. JAMA 325, 467–475 (2021).
Zarrei, M. et al. De novo and rare inherited copy-number variations in the hemiplegic form of cerebral palsy. Genet. Med. 20, 172–180 (2018).
Takezawa, Y. et al. Genomic analysis identifies masqueraders of full-term cerebral palsy. Ann. Clin. Transl. Neurol. 5, 538–551 (2018).
Kayumi, S. et al. Genomic and phenotypic characterization of 404 individuals with neurodevelopmental disorders caused by CTNNB1 variants. Genet. Med. 24, 2351–2366 (2022).
Srivastava, S. et al. Molecular diagnostic yield of exome sequencing and chromosomal microarray in cerebral palsy: a systematic review and meta-analysis. JAMA Neurol. 79, 1287–1295 (2022).
Pearson, T. S., Pons, R., Ghaoui, R. & Sue, C. M. Genetic mimics of cerebral palsy. Mov. Disord. 34, 625–636 (2019).
MacLennan, A. H. et al. Genetic or other causation should not change the clinical diagnosis of cerebral palsy. J. Child Neurol. 34, 472–476 (2019).
Hale, A. T. et al. Genome-wide association study identifies genetic risk factors for spastic cerebral palsy. Neurosurgery 89, 435–442 (2021).
Corbett, M. A. et al. Pathogenic copy number variants that affect gene expression contribute to genomic burden in cerebral palsy. NPJ Genom. Med. 3, 33 (2018).
McMichael, G. et al. Rare copy number variation in cerebral palsy. Eur. J. Hum. Genet. 22, 40–45 (2014).
Oskoui, M. Disentangling racial and ethnic disparities in cerebral palsy. Dev. Med. Child Neurol. 57, 791–792 (2015).
McMichael, G. et al. Whole-exome sequencing points to considerable genetic heterogeneity of cerebral palsy. Mol. Psychiatry 20, 176–182 (2015).
Kadotani, T., Watanabe, Y., Saito, T., Sawano, K. & Minatozaki, K. A chromosomal study on 100 cases of cerebral palsy. Int. J. Hum. Genet. 1, 109–112 (2001).
Oskoui, M. et al. Clinically relevant copy number variations detected in cerebral palsy. Nat. Commun. 6, 7949 (2015).
van Eyk, C. L. et al. Yield of clinically reportable genetic variants in unselected cerebral palsy by whole genome sequencing. NPJ Genom. Med. 6, 74 (2021).
Pham, R. et al. Definition and diagnosis of cerebral palsy in genetic studies: a systematic review. Dev. Med. Child Neurol. 62, 1024–1030 (2020).
Costain, G. et al. Genome sequencing as a diagnostic test in children with unexplained medical complexity. JAMA Netw. Open 3, e2018109 (2020).
Trost, B. et al. Genome-wide detection of tandem DNA repeats that are expanded in autism. Nature 586, 80–86 (2020).
Trost, B. et al. Genomic architecture of autism from comprehensive whole-genome sequence annotation. Cell 148, 4409–4427.e4418 (2022).
Haque, B. et al. Contemporary aetiologies of medical complexity in children: a cohort study. Arch. Dis. Child. 108, 147–149 (2023).
Darnell, J. C. et al. FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism. Cell 146, 247–261 (2011).
Cheng, F. et al. Comprehensive characterization of protein-protein interactions perturbed by disease mutations. Nat. Genet. 53, 342–353 (2021).
Ramazi, S. & Zahiri, J. Posttranslational modifications in proteins: resources, tools and prediction methods. Database https://doi.org/10.1093/database/baab012 (2021).
Evans, R. et al. Protein complex prediction with AlphaFold-Multimer. Preprint at bioRxiv https://doi.org/10.1101/2021.10.04.463034 (2021).
Wan, J. et al. Mutations in the RNA exosome component gene EXOSC3 cause pontocerebellar hypoplasia and spinal motor neuron degeneration. Nat. Genet. 44, 704–708 (2012).
Fu, Y. et al. RGS-insensitive G-protein mutations to study the role of endogenous RGS proteins. Methods Enzymol. 389, 229–243 (2004).
Yokoi, S. et al. TUBA1A mutation can cause a hydranencephaly-like severe form of cortical dysgenesis. Sci. Rep. 5, 15165 (2015).
Okumura, A. et al. A patient with a GNAO1 mutation with decreased spontaneous movements, hypotonia, and dystonic features. Brain Dev. 40, 926–930 (2018).
Gonzalez-Mantilla, P. J. et al. Diagnostic yield of exome sequencing in cerebral palsy and implications for genetic testing guidelines: a systematic review and meta-analysis. JAMA Pediatr. 177, 472–478 (2023).
Lanfranconi, S. & Markus, H. S. COL4A1 mutations as a monogenic cause of cerebral small vessel disease: a systematic review. Stroke 41, e513–e518 (2010).
Meuwissen, M. E. et al. The expanding phenotype of COL4A1 and COL4A2 mutations: clinical data on 13 newly identified families and a review of the literature. Genet. Med. 17, 843–853 (2015).
Yoneda, Y. et al. Phenotypic spectrum of COL4A1 mutations: porencephaly to schizencephaly. Ann. Neurol. 73, 48–57 (2013).
Khalid, R. et al. COL4A1 and fetal vascular origins of schizencephaly. Neurology 90, 232–234 (2018).
Costain, G. et al. Periodic reanalysis of whole-genome sequencing data enhances the diagnostic advantage over standard clinical genetic testing. Eur. J. Hum. Genet. 26, 740–744 (2018).
Morton, S. U. et al. Multicenter consensus approach to evaluation of neonatal hypotonia in the genomic era: a review. JAMA Neurol. 79, 405–413 (2022).
Kingsmore, S. F. et al. A genome sequencing system for universal newborn screening, diagnosis, and precision medicine for severe genetic diseases. Am. J. Hum. Genet. 109, 1605–1619 (2022).
Donn, S. M., Chiswick, M. L. & Fanaroff, J. M. Medico-legal implications of hypoxic-ischemic birth injury. Semin. Fetal Neonatal Med. 19, 317–321 (2014).
Chiurazzi, P. & Pirozzi, F. Advances in understanding—genetic basis of intellectual disability. F1000Res. https://doi.org/10.12688/f1000research.7134.1 (2016).
Brown, S. A. et al. Holoprosencephaly due to mutations in ZIC2, a homologue of Drosophila odd-paired. Nat. Genet. 20, 180–183 (1998).
Depienne, C. & Mandel, J. L. 30 years of repeat expansion disorders: what have we learned and what are the remaining challenges? Am. J. Hum. Genet. 108, 764–785 (2021).
Marshall, C. R. et al. Contribution of copy number variants to schizophrenia from a genome-wide study of 41,321 subjects. Nat. Genet. 49, 27–35 (2017).
Mojarad, B. A. et al. Genome-wide tandem repeat expansions contribute to schizophrenia risk. Mol. Psychiatry 27, 3692–3698 (2022).
Wen, J. et al. Rare tandem repeat expansions associate with genes involved in synaptic and neuronal signaling functions in schizophrenia. Mol. Psychiatry 28, 475–482 (2023).
Tu, W. et al. DAPK1 interaction with NMDA receptor NR2B subunits mediates brain damage in stroke. Cell 140, 222–234 (2010).
Chen, Y. et al. Clinical and genetic heterogeneity in a cohort of Chinese children with dopa-responsive dystonia. Front. Pediatr. 8, 83 (2020).
Diaz Heijtz, R., Almeida, R., Eliasson, A. C. & Forssberg, H. Genetic variation in the dopamine system influences intervention outcome in children with cerebral palsy. eBioMedicine 28, 162–167 (2018).
Wijemanne, S. & Jankovic, J. Dopa-responsive dystonia–clinical and genetic heterogeneity. Nat. Rev. Neurol. 11, 414–424 (2015).
Fink, J. K. Hereditary spastic paraplegia: clinical principles and genetic advances. Semin. Neurol. 34, 293–305 (2014).
Trost, B. et al. Impact of DNA source on genetic variant detection from human whole-genome sequencing data. J. Med. Genet. 56, 809–817 (2019).
Jacquemont, S. et al. Genes to mental health (G2MH): a framework to map the combined effects of rare and common variants on dimensions of cognition and psychopathology. Am. J. Psychiatry 179, 189–203 (2022).
Zarrei, M. et al. Gene copy number variation and pediatric mental health/neurodevelopment in a general population. Hum. Mol. Genet. 32, 2411–2421 (2023).
Hamdan, F. F. et al. High rate of recurrent de Novo mutations in developmental and epileptic encephalopathies. Am. J. Hum. Genet. 101, 664–685 (2017).
Jurgens, J. A. et al. Novel variants in TUBA1A cause congenital fibrosis of the extraocular muscles with or without malformations of cortical brain development. Eur. J. Hum. Genet. 29, 816–826 (2021).
Hamdan, F. F. et al. De novo mutations in moderate or severe intellectual disability. PLoS Genet. 10, e1004772 (2014).
Moraes, T. J. et al. The Canadian healthy infant longitudinal development birth cohort study: biological samples and biobanking. Paediatr. Perinat. Epidemiol. 29, 84–92 (2015).
Purcell, S. et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet. 81, 559–575 (2007).
Yang, J., Lee, S. H., Goddard, M. E. & Visscher, P. M. GCTA: a tool for genome-wide complex trait analysis. Am. J. Hum. Genet. 88, 76–82 (2011).
1000 Genomes Project Consortium et al. A global reference for human genetic variation. Nature 526, 68–74 (2015).
Bergström, A. et al. Insights into human genetic variation and population history from 929 diverse genomes. Science https://doi.org/10.1126/science.aay5012 (2020).
Manichaikul, A. et al. Robust relationship inference in genome-wide association studies. Bioinformatics 26, 2867–2873 (2010).
Yuen, R. K. C. et al. Whole genome sequencing resource identifies 18 new candidate genes for autism spectrum disorder. Nat. Neurosci. 20, 602–611 (2017).
Abyzov, A., Urban, A. E., Snyder, M. & Gerstein, M. CNVnator: an approach to discover, genotype, and characterize typical and atypical CNVs from family and population genome sequencing. Genome Res. 21, 974–984 (2011).
Zhu, M. et al. Using ERDS to infer copy-number variants in high-coverage genomes. Am. J. Hum. Genet. 91, 408–421 (2012).
Trost, B. et al. A comprehensive workflow for read depth-based identification of copy-number variation from whole-genome sequence data. Am. J. Hum. Genet. 102, 142–155 (2018).
Chen, X. et al. Manta: rapid detection of structural variants and indels for germline and cancer sequencing applications. Bioinformatics 32, 1220–1222 (2016).
Rausch, T. et al. DELLY: structural variant discovery by integrated paired-end and split-read analysis. Bioinformatics 28, i333–i339 (2012).
Lott, M. T. et al. mtDNA variation and analysis using Mitomap and Mitomaster. Curr. Protoc. Bioinformatics 44, 1.23.1–1.23.26 (2013).
Andrews, R. M. et al. Reanalysis and revision of the Cambridge reference sequence for human mitochondrial DNA. Nat. Genet. 23, 147 (1999).
Dolzhenko, E. et al. ExpansionHunter: a sequence-graph-based tool to analyze variation in short tandem repeat regions. Bioinformatics 35, 4754–4756 (2019).
Dolzhenko, E. et al. ExpansionHunter Denovo: a computational method for locating known and novel repeat expansions in short-read sequencing data. Genome Biol. 21, 102 (2020).
Karczewski, K. J. et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature 581, 434–443 (2020).
Zarrei, M. et al. A large data resource of genomic copy number variation across neurodevelopmental disorders. NPJ Genom. Med. 4, 26 (2019).
Zarrei, M., MacDonald, J. R., Merico, D. & Scherer, S. W. A copy number variation map of the human genome. Nat. Rev. Genet. 16, 172–183 (2015).
MacDonald, J. R., Ziman, R., Yuen, R. K., Feuk, L. & Scherer, S. W. The database of genomic variants: a curated collection of structural variation in the human genome. Nucleic Acids Res. 42, D986–D992 (2014).
Jaganathan, K. et al. Predicting splicing from primary sequence with deep learning. Cell 176, 535–548.e524 (2019).
Xiong, H. Y. et al. RNA splicing. The human splicing code reveals new insights into the genetic determinants of disease. Science 347, 1254806 (2015).
Jian, X., Boerwinkle, E. & Liu, X. In silico prediction of splice-altering single nucleotide variants in the human genome. Nucleic Acids Res. 42, 13534–13544 (2014).
Landrum, M. J. et al. ClinVar: public archive of interpretations of clinically relevant variants. Nucleic Acids Res. 44, D862–D868 (2016).
Richards, S. et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet. Med. 17, 405–424 (2015).
Riggs, E. R. et al. Technical standards for the interpretation and reporting of constitutional copy-number variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics (ACMG) and the Clinical Genome Resource (ClinGen). Genet. Med. 22, 245–257 (2020).
McCormick, E. M. et al. Specifications of the ACMG/AMP standards and guidelines for mitochondrial DNA variant interpretation. Hum. Mutat. 41, 2028–2057 (2020).
Manshaei, R. et al. Genes and pathways implicated in tetralogy of Fallot revealed by ultra-rare variant burden analysis in 231 genome sequences. Front. Genet. 11, 957 (2020).
Pinese, M. et al. The Medical Genome Reference Bank contains whole genome and phenotype data of 2570 healthy elderly. Nat. Commun. 11, 435 (2020).
Schubert, E., Sander, J., Ester, M., Kriegel, H. P. & Xu, X. DBSCAN revisited, revisited: why and how you should (still) use DBSCAN. ACM Trans. Database Syst. 42, 19 (2017).
Fehlings, D. L. et al. CP-NET Clinical Database Platform: genomic architecture of CP (whole genome sequencing). Brain-CODE, https://doi.org/10.60955/fszr-5q79 (2024).
Acknowledgements
This research was conducted in part through the Childhood Cerebral Palsy Neuroscience Discovery Network (CP-NET) with the support of the Ontario Brain Institute, an independent nonprofit corporation, funded by the Ontario Government. The present study was also funded by Project Grants from the Canadian Institutes of Health Research (grant nos. PJT-153004 and PJT-175329 to R.K.C.Y.), the Research Foundation of the Cerebral Palsy Alliance (grant no. PG4516), Debbie and Don Morrison for support of the CHILD study and the University of Toronto McLaughlin Centre. The Canadian CP Registry was funded by Kids Brain Health Network. R.K.C.Y. is supported by the Hospital for Sick Children’s Research Institute, SickKids Catalyst Scholar in Genetics, Brain Canada and the Azrieli Foundation. CHILD was initially funded by CIHR and AllerGen NCE, and receives support from Women and Children’s Health Research Institute at the University of Alberta (to P.M.). Work at The Centre for Applied Genomics (TCAG) at the Hospital for Sick Children is funded by the Canada Foundation for Innovation (CGEn-MSI, Innovation Fund) and Genome Canada through Ontario Genomics. We thank M. Lorenti for technical assistance with sample preparation and V. Jha, J. Sangster and S. McPherson for assistance with variant validation. We acknowledge Illumina, Inc. for providing sequencing reagents for the CHILD and Inova control cohorts. M.B.A., P.S. and S.E.T. hold Canada Research Chairs. M.O. is a Research Scholar of the Fonds de Recherche du Québec-Santé. During the work presented in this article, J.W.G. held the Scotiabank Chair in Child Health Research at McMaster University. S.W.S. holds the Northbridge Chair in Paediatric Research, a joint hospital–university chair across the University of Toronto, the Hospital for Sick Children and the SickKids Foundation. We thank all participant families for their dedication and commitment to advancing health research.
Author information
Authors and Affiliations
Contributions
D.L.F., R.F.W., M.O., M.Z., W.E., S.W.S., A. McCormick, A. Kirton, C.H., D.S., J.W.G., N.D., R. Mesterman, S.K., M.S. and A. Kawamura conceived the project. D.L.F., M.O., A. McCormick, A. Kirton, C.H., D.S., J.W.G., N.D. R. Mesterman, S.K., M.S., A. Kawamura and R.F.W. collected the data. M.Z., B. Trost, W.E., J.R.M., E.J.H., B. Thiruvahindrapuram, M.B.A., G.P., J. Wei, R.F.W., R.K.C.Y., S.W.S., D.L.F., M.O., N.S., P.S., S.E.T., P.M., T.J.M., E.S., G.M., D.M., D.J.S., R. Manshaei, T.N., R.S., S.G., K. Ho, J.d.R., W.W.L.S., A. Mowjoodi, G.C., J.L.M., C.R.M., F.F.H., J.G. and K.U. provided the methodology and interpreted the data. S.L., J.d.R., M.H., K. Han, K.G., N.X.B. and K. Hirschfeld validated the data. S.W.S., D.L.F. and M.O. provided the resources. B. Thiruvahindrapuram, J.R.M., J.W., P.M., P.S.D., R.V.P., O.H. and W.W.L.S. curated the data. W.E. and G.P. visualized the data. S.W.S., D.L.F., M.O. and R.F.W. supervised the project. R.F.W., S.L.P., S.A., R.T., P.N., T.B., L.S. and J.L.H. were project administrators. S.W.S., D.L.F., R.F.W., A. McCormick, A. Kirton, C.H., D.S., J.W.G., N.D., R. Mesterman, S.K., M.O., M.S. and A. Kawamura acquired the funding.
Corresponding author
Ethics declarations
Competing interests
Illumina, Inc. provided sequencing reagents for the CHILD and Inova control cohorts. S.W.S. is on the Scientific Advisory Committee of Population Bio, Inc. and serves as a Highly Cited Academic Advisor for the King Abdulaziz University. R.F.W. discloses consulting activities for Guidepoint Global, GLG and Bioinformatics LLC, not related to the present study. D.M. was employed by Deep Genomics at the time of the study and some annotation tools were provided by Deep Genomics. D.J.S. has equity in PhenoTips. The other authors declare no competing interests.
Peer review
Peer review information
Nature Genetics thanks Jozef Gecz and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Peer reviewer reports are available.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Supplementary Information
Supplementary Table Information, Note 1 and Figs. 1–3.
Supplementary Tables
Supplementary Tables 1–10 in a single Excel file with multiple worksheets.
Supplementary Data 1
Source data used to generate Supplementary Table 2.
Source data
Source Data Fig. 1
Data in Excel that were used to generate Fig. 1.
Source Data Fig. 2
Data in Excel that were used to generate Fig. 2.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Fehlings, D.L., Zarrei, M., Engchuan, W. et al. Comprehensive whole-genome sequence analyses provide insights into the genomic architecture of cerebral palsy. Nat Genet 56, 585–594 (2024). https://doi.org/10.1038/s41588-024-01686-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41588-024-01686-x
- Springer Nature America, Inc.